Citation Impact
Citing Papers
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
2017
Psoriasis
2021 Standout
Psoriasis: Which therapy for which patient
2018
Psoriasis pathogenesis and the development of novel targeted immune therapies
2017
Hidradenitis suppurativa
2020 Standout
Psoriasis
2016
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
2018
Comparison of Biologics and Oral Treatments for Plaque Psoriasis
2020
Psoriasis Pathogenesis and Treatment
2019 Standout
Proenkephalin+regulatory T cells expanded by ultraviolet B exposure maintain skin homeostasis with a healing function
2020 StandoutNobel
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis
2020 Standout
Works of D. Toth being referenced
A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis
2016